Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received
European Urology Feb 19, 2020
Neal DE, Metcalfe C, Donovan JL et al. - This study was intended to ascertain report outcomes according to treatment received in men in randomized and treatment choice cohorts. Researchers performed two cohorts including a total of 1,643 men who agreed to be randomized; 997 declined randomization and chose treatment. Using patient-reported outcome measures, health-related quality of life impacts urinary, bowel, and sexual function were investigated. By utilizing propensity scores, differences were calculated with adjustment for known prognostic factors. Investigations according to treatment received showed increased rates of disease-related events and lower rates of patient-reported harms in men managed by AM in comparison with men managed by radical treatment and the stronger sign of greater PCa mortality in the AM group.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries